Attention is focusing on whether the reimbursement standards for Enhertu, an anti-cancer drug from Daiichi Sankyo Korea, will be prepared through re-discussion by the Cancer Disease Review Committee. The drug has received more than 50,000 national petitions and is currently accelerating its reimbursement review. However, at the HIRA held last month, it was decided to discuss again without reaching a conclusion on the setting of the salary standard. According to the industry on the 14th, Enhertu's Daiichi Sankyo recently submitted complementary data to HIRA.
Previously, at the review committee held on the 22nd of last month, supplementary data was requested on the grounds that the level of evidence for Enhertu's